Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Zepatier

- PMLiVE

Merck says osteoporosis drug clears phase II trial

Odanacatib on track for 2013 filing

- PMLiVE

Merck & Co relocates global headquarters

Leaves Whitehouse Station for new site in New Jersey

- PMLiVE

Merck & Co says Januvia follow-up looking good

Diabetes drug shows promise in phase II as once-weekly treatment

- PMLiVE

Janssen and Merck & Co share UK Prix Galien for hepatitis C drugs

Incivo and Victrelis joint winners of Innovative Product Award

- PMLiVE

Janssen and Merck & Co share UK Prix Galien for hepatitis C drugs

Incivo and Victrelis joint winners of Innovative Product Award

Merck’s new insomnia drug clears phase III trial

Novel method of treatment offers fewer side effects

Bristol-Myers Squibb (BMS) building

BMS halts hep C candidate development after patient death

Promises to share drug data to assist other pharma companies’ patient safety measures

Bristol-Myers Squibb (BMS) building

BMS halts trial of hepatitis C drug on safety issues

At least one person in study thought to have developed congestive heart failure

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links